JP3245578B2 - ピロリジニルヒドロキサム酸化合物の製造方法 - Google Patents
ピロリジニルヒドロキサム酸化合物の製造方法Info
- Publication number
- JP3245578B2 JP3245578B2 JP18308699A JP18308699A JP3245578B2 JP 3245578 B2 JP3245578 B2 JP 3245578B2 JP 18308699 A JP18308699 A JP 18308699A JP 18308699 A JP18308699 A JP 18308699A JP 3245578 B2 JP3245578 B2 JP 3245578B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- hydroxy
- give
- following formula
- following structure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims description 56
- -1 pyrrolidinyl hydroxamic Chemical compound 0.000 title claims description 14
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 239000002253 acid Substances 0.000 title description 8
- 238000006243 chemical reaction Methods 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 8
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- CJJURHKDGQSBLE-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)acetyl chloride Chemical compound ClC(=O)CC1=CC=C(Cl)C(Cl)=C1 CJJURHKDGQSBLE-UHFFFAOYSA-N 0.000 claims description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 claims description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- VMWJUQZGLCWWDV-UHFFFAOYSA-N acetamide;4-methylbenzenesulfonic acid Chemical compound CC(N)=O.CC1=CC=C(S(O)(=O)=O)C=C1 VMWJUQZGLCWWDV-UHFFFAOYSA-N 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- 239000002002 slurry Substances 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical group CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000001475 halogen functional group Chemical group 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 102000051367 mu Opioid Receptors Human genes 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000000018 receptor agonist Substances 0.000 description 3
- 229940044601 receptor agonist Drugs 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 108020001612 μ-opioid receptors Proteins 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000003840 Opioid Receptors Human genes 0.000 description 2
- 108090000137 Opioid Receptors Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000005695 dehalogenation reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000004090 neuroprotective agent Substances 0.000 description 2
- XYEOALKITRFCJJ-UHFFFAOYSA-N o-benzylhydroxylamine Chemical compound NOCC1=CC=CC=C1 XYEOALKITRFCJJ-UHFFFAOYSA-N 0.000 description 2
- 239000000014 opioid analgesic Substances 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- QVPCHUSMYXRTHF-UHFFFAOYSA-N (1-benzylpyrrolidin-3-yl) benzoate Chemical compound C=1C=CC=CC=1C(=O)OC(C1)CCN1CC1=CC=CC=C1 QVPCHUSMYXRTHF-UHFFFAOYSA-N 0.000 description 1
- PSWCFHRUHDIKNU-UHFFFAOYSA-N (2-hydroxy-2-phenylethyl) benzoate Chemical compound C=1C=CC=CC=1C(O)COC(=O)C1=CC=CC=C1 PSWCFHRUHDIKNU-UHFFFAOYSA-N 0.000 description 1
- MVVCJIVSQDJOOR-VKLKMBQZSA-N 2-(2-aminophenyl)-n-[(1s)-2-[(3s)-3-hydroxypyrrolidin-1-yl]-1-phenylethyl]-n-methylacetamide;hydrochloride Chemical compound Cl.C([C@@H](N(C)C(=O)CC=1C(=CC=CC=1)N)C=1C=CC=CC=1)N1CC[C@H](O)C1 MVVCJIVSQDJOOR-VKLKMBQZSA-N 0.000 description 1
- ZOUPGSMSNQLUNW-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(Cl)C(Cl)=C1 ZOUPGSMSNQLUNW-UHFFFAOYSA-N 0.000 description 1
- VPHHJAOJUJHJKD-UHFFFAOYSA-M 3,4-dichlorobenzoate Chemical compound [O-]C(=O)C1=CC=C(Cl)C(Cl)=C1 VPHHJAOJUJHJKD-UHFFFAOYSA-M 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- BVJLZDPKDUNKSD-UHFFFAOYSA-N O=C(C1(CC(C2=CC=CC=C2)Cl)C=CC=CC1)OC1CNCC1 Chemical compound O=C(C1(CC(C2=CC=CC=C2)Cl)C=CC=CC1)OC1CNCC1 BVJLZDPKDUNKSD-UHFFFAOYSA-N 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 108070000021 Opioid peptides receptors Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- ZSGBQTNBVGQGTO-UHFFFAOYSA-N acetamido 4-methylbenzenesulfonate Chemical compound CC(=O)NOS(=O)(=O)C1=CC=C(C)C=C1 ZSGBQTNBVGQGTO-UHFFFAOYSA-N 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 238000006392 deoxygenation reaction Methods 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 102000048260 kappa Opioid Receptors Human genes 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000003399 opiate peptide Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical compound OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 description 1
- RSCLTAHCZHPGHS-UHFFFAOYSA-N pyrrolidin-3-yl benzoate Chemical compound C=1C=CC=CC=1C(=O)OC1CCNC1 RSCLTAHCZHPGHS-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003334 secondary amides Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 108020001588 κ-opioid receptors Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9763398P | 1998-08-24 | 1998-08-24 | |
| US60/097633 | 1998-08-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2000072744A JP2000072744A (ja) | 2000-03-07 |
| JP3245578B2 true JP3245578B2 (ja) | 2002-01-15 |
Family
ID=22264376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP18308699A Expired - Fee Related JP3245578B2 (ja) | 1998-08-24 | 1999-06-29 | ピロリジニルヒドロキサム酸化合物の製造方法 |
Country Status (18)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03009927A (es) | 2001-04-30 | 2004-01-29 | Pfizer Prod Inc | Procedimiento para preparar compuestos de hidroxipirrolidinietilamina utiles como agonistas de kappa. |
| AU2003269399A1 (en) * | 2002-11-01 | 2004-05-25 | Pfizer Products Inc. | Process for the preparation of pyrrolidinyl ethylamine compounds via a copper-mediated aryl amination |
| US8057664B2 (en) * | 2005-11-17 | 2011-11-15 | Exxonmobil Chemical Patents, Inc. | Process for reducing bromine index of hydrocarbon feedstocks |
| US7744750B2 (en) * | 2005-11-17 | 2010-06-29 | Exxonmobil Chemical Patents Inc. | Process for reducing Bromine Index of hydrocarbon feedstocks |
| US7517824B2 (en) * | 2005-12-06 | 2009-04-14 | Exxonmobil Chemical Company | Process for steam stripping hydrocarbons from a bromine index reduction catalyst |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996030339A1 (en) | 1995-03-31 | 1996-10-03 | Pfizer Inc. | Pyrrolidinyl hydroxamic acid compounds and their production process |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8618188D0 (en) * | 1986-07-25 | 1986-09-03 | Ici Plc | Diamine compounds |
| IE61631B1 (en) * | 1988-05-20 | 1994-11-16 | Zambon Spa | Compounds with central analgesic activity, process for their preparation and pharmaceutical compositions containing them |
| DE4034785A1 (de) * | 1990-11-02 | 1992-05-07 | Merck Patent Gmbh | 1-(2-arylethyl)-pyrrolidine |
| KR0132001B1 (ko) * | 1994-05-21 | 1998-04-17 | 강박광 | 신규한 치환된 이미다졸 유도체 |
| MX9701042A (es) * | 1996-02-07 | 1998-05-31 | Pfizer | Compuestos del acido hidroxamico. |
| TNSN97092A1 (ar) * | 1996-09-18 | 1999-12-31 | Agouron Pharma | مثبطات انزيم بروتيني فلزي وتركيبات صيدلانية تحتوي على تلك المثبتطات واستخدامها الصيدلاني وطرق ومركبات وسيطة مفيدة لتحضير التركيبات المذكورة. |
-
1999
- 1999-06-10 IL IL13042999A patent/IL130429A0/xx unknown
- 1999-06-10 EP EP99304531A patent/EP0982297A3/en not_active Withdrawn
- 1999-06-11 HU HU9901944A patent/HUP9901944A3/hu unknown
- 1999-06-15 RU RU99113363/04A patent/RU2163235C1/ru not_active IP Right Cessation
- 1999-06-17 AR ARP990102917A patent/AR016500A1/es not_active Application Discontinuation
- 1999-06-17 IN IN883DE1999 patent/IN190844B/en unknown
- 1999-06-29 JP JP18308699A patent/JP3245578B2/ja not_active Expired - Fee Related
- 1999-06-30 ZA ZA9904285A patent/ZA994285B/xx unknown
- 1999-06-30 CA CA002277242A patent/CA2277242A1/en not_active Abandoned
- 1999-07-01 ID IDP990637D patent/ID23462A/id unknown
- 1999-07-01 BR BR9902525-6A patent/BR9902525A/pt not_active IP Right Cessation
- 1999-07-01 YU YU31499A patent/YU31499A/sh unknown
- 1999-07-01 PL PL99334144A patent/PL334144A1/xx unknown
- 1999-07-01 CN CN99108932A patent/CN1245799A/zh active Pending
- 1999-07-01 KR KR1019990026361A patent/KR100338916B1/ko not_active Expired - Fee Related
- 1999-07-02 TR TR1999/01546A patent/TR199901546A2/xx unknown
- 1999-08-16 US US09/374,869 patent/US6031114A/en not_active Expired - Fee Related
- 1999-08-23 AU AU44665/99A patent/AU4466599A/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996030339A1 (en) | 1995-03-31 | 1996-10-03 | Pfizer Inc. | Pyrrolidinyl hydroxamic acid compounds and their production process |
Also Published As
| Publication number | Publication date |
|---|---|
| YU31499A (sh) | 2002-11-15 |
| HUP9901944A2 (hu) | 2000-06-28 |
| TR199901546A3 (tr) | 2000-04-21 |
| CN1245799A (zh) | 2000-03-01 |
| RU2163235C1 (ru) | 2001-02-20 |
| EP0982297A3 (en) | 2001-08-01 |
| IL130429A0 (en) | 2000-06-01 |
| AR016500A1 (es) | 2001-07-04 |
| US6031114A (en) | 2000-02-29 |
| TR199901546A2 (xx) | 2000-04-21 |
| EP0982297A2 (en) | 2000-03-01 |
| JP2000072744A (ja) | 2000-03-07 |
| AU4466599A (en) | 2000-03-09 |
| CA2277242A1 (en) | 2000-02-24 |
| BR9902525A (pt) | 2000-05-02 |
| IN190844B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2003-08-23 |
| ZA994285B (en) | 2001-01-02 |
| ID23462A (id) | 2000-04-27 |
| KR20000016898A (ko) | 2000-03-25 |
| PL334144A1 (en) | 2000-02-28 |
| HU9901944D0 (en) | 1999-08-30 |
| HUP9901944A3 (en) | 2001-10-29 |
| KR100338916B1 (ko) | 2002-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0570463A (ja) | Ｎ−アシル−２，３−ベンゾジアゼピン誘導体、その製造法、それを含有する製剤組成物、およびその製造法 | |
| EP1853557A2 (fr) | Derives de 1,5-diarylpyrrole, leur preparation et leur application en therapeutique | |
| WO2003093220A1 (en) | Process for preparing highly functionalized y-butyrolactams and y-amino acids | |
| JP3035356B2 (ja) | ピロリジニルヒドロキサム酸化合物及びその製造方法 | |
| WO2022214645A1 (en) | Processes and intermediates for the preparation of relugolix | |
| EP2094656B1 (fr) | Derives de pyrrole, leur preparation et leur utilisation en therapeutique. | |
| JP3245578B2 (ja) | ピロリジニルヒドロキサム酸化合物の製造方法 | |
| EP1899298A2 (fr) | Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique | |
| JP2000516634A (ja) | カッパアゴニストとしてのピロリジニルおよびピロリニルエチルアミン化合物 | |
| AU2003248428B2 (en) | Process for the preparation of enantiomerically pure N-methyl-N-[(1S)-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide | |
| JP3213324B2 (ja) | 新規なｎ−ベンゾイルメチル−ピペリジン類 | |
| HU177798B (en) | Process for producing substituted pyrrolydines | |
| JPH037280A (ja) | 新規ベンゾチオピラニルアミン | |
| JP4574944B2 (ja) | ジスタマイシン誘導体の調製方法 | |
| HUT77316A (hu) | 6-Metoxi-1H-benzotriazol-5-karboxamid-származékok, ezek előállítási eljárása és ilyen vegyületeket tartalmazó gyógyszerkészítmények | |
| JPH04290870A (ja) | アミン誘導体の製造方法 | |
| MXPA99006264A (en) | Procedure for pirrolidinyl hydroxam acid compounds | |
| CZ9902390A3 (cs) | Způsob výroby derivátů pyrrolidinylhydroxamové kyseliny | |
| JP3159518B2 (ja) | アミノ置換スピロ化合物の製法 | |
| JP2008525512A (ja) | ５−ｈｔ７受容体拮抗薬 | |
| CA3215792A1 (en) | Processes for the synthesis of valbenazine | |
| JPH1112250A (ja) | カッパアゴニストとしてのヒドラジド化合物 | |
| JP2010526126A (ja) | バルサルタンの製造方法 | |
| HK1025966A (en) | Process for pyrrolidinyl hydroxamic acid compounds | |
| EP2152697A2 (en) | Process for the preparation of alfuzosin and salts thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |